Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C34H35N3O10 |
| Molecular Weight | 645.6558 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 6 / 6 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]1(C[C@@](O)(CC2=C(O)C3=C(C(=O)C4=C(C=CC=C4OC)C3=O)C(O)=C12)C(C)=NNC(=O)C5=CC=CC=C5)O[C@H]6C[C@H](N)[C@H](O)[C@H](C)O6
InChI
InChIKey=FBTUMDXHSRTGRV-BJISBDEGSA-N
InChI=1S/C34H35N3O10/c1-15-28(38)20(35)12-23(46-15)47-22-14-34(44,16(2)36-37-33(43)17-8-5-4-6-9-17)13-19-25(22)32(42)27-26(30(19)40)29(39)18-10-7-11-21(45-3)24(18)31(27)41/h4-11,15,20,22-23,28,38,40,42,44H,12-14,35H2,1-3H3,(H,37,43)/t15-,20-,22-,23-,28+,34-/m0/s1
Zorubicin is a benzoylhydrazone derivative of the anthracycline antineoplastic antibiotic daunorubicin, but it introduces lower cardiomyopathy and bone marrow toxicity. Zorubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair as well as RNA and protein synthesis. The cytotoxic effect results from intercalation between DNA pairs. To minimize toxicity, individualized dose regimens are given preferentially over prolonged periods of time by carefully inspecting i.v. administration to prevent extravasation.
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C1594
Created by
admin on Fri Dec 15 16:07:09 GMT 2023 , Edited by admin on Fri Dec 15 16:07:09 GMT 2023
|
||
|
WHO-VATC |
QL01DB05
Created by
admin on Fri Dec 15 16:07:09 GMT 2023 , Edited by admin on Fri Dec 15 16:07:09 GMT 2023
|
||
|
WHO-ATC |
L01DB05
Created by
admin on Fri Dec 15 16:07:09 GMT 2023 , Edited by admin on Fri Dec 15 16:07:09 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
ZORUBICIN
Created by
admin on Fri Dec 15 16:07:09 GMT 2023 , Edited by admin on Fri Dec 15 16:07:09 GMT 2023
|
PRIMARY | |||
|
V25F9362OP
Created by
admin on Fri Dec 15 16:07:09 GMT 2023 , Edited by admin on Fri Dec 15 16:07:09 GMT 2023
|
PRIMARY | |||
|
m11665
Created by
admin on Fri Dec 15 16:07:09 GMT 2023 , Edited by admin on Fri Dec 15 16:07:09 GMT 2023
|
PRIMARY | Merck Index | ||
|
SUB00190MIG
Created by
admin on Fri Dec 15 16:07:09 GMT 2023 , Edited by admin on Fri Dec 15 16:07:09 GMT 2023
|
PRIMARY | |||
|
100000078800
Created by
admin on Fri Dec 15 16:07:09 GMT 2023 , Edited by admin on Fri Dec 15 16:07:09 GMT 2023
|
PRIMARY | |||
|
C002205
Created by
admin on Fri Dec 15 16:07:09 GMT 2023 , Edited by admin on Fri Dec 15 16:07:09 GMT 2023
|
PRIMARY | |||
|
57164040
Created by
admin on Fri Dec 15 16:07:09 GMT 2023 , Edited by admin on Fri Dec 15 16:07:09 GMT 2023
|
PRIMARY | |||
|
2874
Created by
admin on Fri Dec 15 16:07:09 GMT 2023 , Edited by admin on Fri Dec 15 16:07:09 GMT 2023
|
PRIMARY | |||
|
C91365
Created by
admin on Fri Dec 15 16:07:09 GMT 2023 , Edited by admin on Fri Dec 15 16:07:09 GMT 2023
|
PRIMARY | |||
|
DTXSID4043852
Created by
admin on Fri Dec 15 16:07:09 GMT 2023 , Edited by admin on Fri Dec 15 16:07:09 GMT 2023
|
PRIMARY | |||
|
54083-22-6
Created by
admin on Fri Dec 15 16:07:09 GMT 2023 , Edited by admin on Fri Dec 15 16:07:09 GMT 2023
|
PRIMARY | |||
|
CHEMBL1697854
Created by
admin on Fri Dec 15 16:07:09 GMT 2023 , Edited by admin on Fri Dec 15 16:07:09 GMT 2023
|
PRIMARY | |||
|
4349
Created by
admin on Fri Dec 15 16:07:09 GMT 2023 , Edited by admin on Fri Dec 15 16:07:09 GMT 2023
|
PRIMARY | |||
|
DB11618
Created by
admin on Fri Dec 15 16:07:09 GMT 2023 , Edited by admin on Fri Dec 15 16:07:09 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
